NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name (Descending) | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
57377-0050-01 | 57377-0050 | Estradiol pellet | Estra-50 | 50.0 mg/1 | Hormonal Therapy | Estrogen | Subcutaneous | Jan. 1, 2017 | In Use | ||
57377-0025-01 | 57377-0025 | Estradiol pellet | Estra-25 | 25.0 mg/1 | Hormonal Therapy | Estrogen | Subcutaneous | Jan. 1, 2017 | In Use | ||
57902-0249-05 | 57902-0249 | Asparaginase | Erwinaze | 10000.0 [iU]/mL | Chemotherapy | Miscellaneous Agent | Enzyme | Intramuscular, Intravenous | Nov. 18, 2011 | July 23, 2021 | No Longer Used |
00378-7131-93 | 00378-7131 | erlotinib hydrochloride | Erlotinib Hydrochloride | 25.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Oral | May 9, 2019 | Nov. 30, 2022 | No Longer Used |
00378-7132-93 | 00378-7132 | erlotinib hydrochloride | Erlotinib Hydrochloride | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Oral | May 9, 2019 | Nov. 30, 2022 | No Longer Used |
00378-7133-93 | 00378-7133 | erlotinib hydrochloride | Erlotinib Hydrochloride | 150.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Oral | May 9, 2019 | Nov. 30, 2022 | No Longer Used |
42292-0051-05 | 42292-0051 | Erlotinib hydrochloride | Erlotinib Hydrochloride | 25.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Oral | May 28, 2019 | Jan. 31, 2021 | No Longer Used |
42292-0052-05 | 42292-0052 | Erlotinib hydrochloride | Erlotinib Hydrochloride | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Oral | May 28, 2019 | Feb. 28, 2021 | No Longer Used |
42292-0053-05 | 42292-0053 | Erlotinib hydrochloride | Erlotinib Hydrochloride | 150.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Oral | May 28, 2019 | Jan. 31, 2021 | No Longer Used |
69539-0091-30 | 69539-0091 | Erlotinib Hydrochloride | Erlotinib Hydrochloride | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Oral | May 11, 2021 | In Use |
Found 10,000 results in 8 milliseconds — Export these results